Análisis opcionales del producto
Con tu permiso, usamos análisis limitados y respetuosos con la privacidad para entender qué recorridos de investigación funcionan. No usamos rastreadores publicitarios ni grabación de sesiones. Puedes cambiar esta opción en Preferencias. Lee la Política de privacidad.
Exact Sciences Corp's published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $20.0B | |
|---|---|---|
| P/E (forward) | 55.2x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | Trend |
|---|---|---|---|---|---|
| Period | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $2.08B | $2.50B | $2.76B | $3.25B | +15.9% |
| Gross profit | $1.42B | $1.76B | $1.92B | $2.26B | +16.7% |
| Operating income | $-618.7M | $-177.3M | $-1.00B | $-169.1M | — |
| Net income | $-623.5M | $-204.1M | $-1.03B | $-207.9M | — |
| EPS (diluted) | $-3.54 | $-1.13 | $-5.59 | $-1.10 | — |
| EBITDA | $-421.1M | $29.3M | $-789.3M | $52.4M | — |
| R&D | $394.2M | $426.9M | $431.2M | $523.0M | +9.9% |
| SG&A | $1.59B | $1.63B | $1.68B | $1.94B | +6.8% |
Recent company headlines from major financial publishers.
Successful Cologuard Plus launch and multi-cancer test expansion drive sustained double-digit growth, scaling margins and expanding terminal multiples.
Continued ~12% revenue growth scaling into strong 70% gross margins. Steady progression toward operating profitability without major multiple compression.
| Ke ↓ / g → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 7.9% | $144 | $157 | $173 | $193 | $216 |
| 8.9% | $123 | $133 | $144 | $157 | $173 |
| 9.9% | $108 | $115 | $123 | $133 | $144 |
| 10.9% | $95.8 | $101 | $108 | $115 | $123 |
| 11.9% | $86.1 | $90.7 | $95.8 | $101 | $108 |
Upcoming earnings date and setup when available.
La calificación que llevaba la edición de análisis publicada cada mes. Una calificación compara el precio en la fecha del análisis con el valor razonable; no es un registro de si la valoración acertó.
| Año | ene | feb | mar | abr | may | jun | jul | ago | sept | oct | nov | dic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
